ReportGem ReportGem

U.S. COMPANY FILING

NOVO NORDISK A S — Form 6-K filed 2025-11-07

Filed: 2025-11-07Company: NOVO NORDISK A STicker: NVOExchange: NYSEForm: 6-KReport period: 2025-11-06SEC accession: 0001171843-25-007120Event: otherMateriality: 8

Filing text preview

Novo Nordisk announced an agreement with the U.S. Administration to lower prices for semaglutide medicines (Wegovy, Ozempic) in Medicare Part D, Medicaid, and cash channel starting 2026, and expand Medicare coverage for obesity drugs via a pilot program. The company expects a negative low single-digit impact on 2026 global sales growth and a three-year tariff exemption.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-11-07Super Micro Says Top Management Didn't Know of Diversion Scheme2026-08-20Deoleo Shareholders Review Strategic Alternatives for Olive-Oil Business2026-08-20SSE Issues Regulatory Work Letter to Nanmo Bio2026-08-20Autohome Inc. files Form 6-K2026-08-20Sadot Group Inc. Files 8-K: Material Definitive Agreement and Unregistered Sales of Equity Securities2026-08-20WANG ON GROUP: Major transaction regarding disposal of target company and notice of extraordinary general meeting2026-08-206-K2026-08-04 · 6-K